new risk management programs with Abstral (AB-stral) and other immediate-release fentanyl products
You'll see new risk management programs with Abstral (AB-stral) and other immediate-release fentanyl products.
Abstral is a new sublingual tab that will compete with the lozenge (Actiq, etc)...buccal tab (Fentora, etc)...and buccal film (Onsolis).
These are ONLY for breakthrough pain in cancer patients who are already on chronic opioids.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote